{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:42Z","timestamp":1787026482146,"version":"build-2736575974"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011635","name":"Fuwai Hospital, Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-008"],"award-info":[{"award-number":["2021-I2M-1-008"]}],"id":[{"id":"10.13039\/501100011635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>\n                    Refractory hypercholesterolemia (RH), including homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia, is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) despite existing cholesterol-lowering methods at maximal tolerable doses. Patients with RH have early onset and higher risk of atherosclerotic cardiovascular disease (ASCVD) under insufficient treatment. Therefore, it is urgent to seek new therapies to maintain the blood lipids in refractory hyperlipidemia at normal levels. Currently, new cholesterol-lowering strategies are on the market, not only at the protein level [i.e., bempedoic acid (inhibiting ATP-citrate lyase), alirocumab and evolocumab (monoclonal antibodies against PCSK9), evinacumab (monoclonal antibody against ANGPTL3)] but also at the transcript level [i.e., mipomersen (antisense oligonucleotide inhibiting ApoB), inclisiran (siRNA targeting PCSK9)], providing more options for RH patients to achieve their lipid-lowering targets. More RNA-based therapies targeting RH-related genes have been designed for the treatment. However, for a proportion of patients, especially those with LDLR deficiency, the available treatments are still insufficient. More recently, emerging genome engineering based on CRISPR\/Cas9 techniques, and advanced delivery technologies such as lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, lipid nanoparticles, and exosomes are being rapidly developed and implemented as novel therapies for RH. Gene therapy targeting RH-related genes has been successfully conducted in cells, mice, and non-human primates with high efficacy in lipid lowering and good tolerability. Especially the new generation of genome editing technique, base editing, performed\n                    <jats:italic>in vivo<\/jats:italic>\n                    with ideal lipid-lowering effect and limited occurrence of unwanted results. Excitingly, a phase I\/II clinical study of LDLR gene replacement has been recently completed in RH patients, likely to be employed in clinical practice in the future. Furthermore, new targets for cholesterol reduction such as REV-ERB, G protein-coupled receptor, Ubiquitin specific peptidase 20 are continually being developed. This narrative review updates recent advances in treatment for RH, summarizes related clinical trials and preclinical studies, especially on the prospect of gene therapy.\n                  <\/jats:p>","DOI":"10.3389\/fgene.2022.911429","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T03:13:51Z","timestamp":1654744431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhi-Fan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","article-title":"New Therapies for Primary Hyperlipidemia","volume":"107","author":"Aguilar-Salinas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"Angptl3 and Apolipoprotein C-Iii as Novel Lipid-Lowering Targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/104303401750061230","article-title":"Engraftment of Autologous Retrovirally Transduced Hepatocytes after Intraportal Transplantation into Nonhuman Primates: Implication Forex VivoGene Therapy","volume":"12","author":"Andreoletti","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome Editing with Crispr-Cas Nucleases, Base Editors, Transposases and Prime Editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B5","first-page":"2","article-title":"Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates Aro-Apoc3 and Aro-Ang3","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A Huge Prevalence Review","volume":"160","author":"Austin","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/sctm.18-0226","article-title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform","volume":"8","author":"Baek","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5694\/mja16.00070","article-title":"Progress in the Care of Familial Hypercholesterolaemia: 2016","volume":"205","author":"Bell","year":"2016","journal-title":"Med. J. Aust."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07293-w","article-title":"Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-clinical Perspective Review","author":"Bellosta","year":"2022","journal-title":"Cardiovasc Drugs Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"Lower, a Registry of Lomitapide-Treated Patients with Homozygous Familial Hypercholesterolemia: Rationale and Design","volume":"10","author":"Blom","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nmeth.3684","article-title":"Creating and Evaluating Accurate Crispr-Cas9 Scalpels for Genomic Surgery","volume":"13","author":"Bolukbasi","year":"2016","journal-title":"Nat. Methods"},{"key":"B13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/13543784.2020.1778668","article-title":"Bempedoic Acid, an Inhibitor of Atp Citrate Lyase for the Treatment of Hypercholesterolemia: Early Indications and Potential","volume":"29","author":"Brandts","year":"2020","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial Hypercholesterolemia","volume":"78","author":"Brandts","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"760140","DOI":"10.3389\/fcvm.2021.760140","article-title":"Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects","volume":"8","author":"Cao","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12915-018-0624-2","article-title":"In Vivo genome and Base Editing of a Human PCSK9 Knock-In Hypercholesterolemic Mouse Model","volume":"17","author":"Carreras","year":"2019","journal-title":"BMC Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced Blood Lipid Levels with In Vivo Crispr-Cas9 Base Editing of Angptl3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) as a Therapeutic Alternative to Genome Editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"Atvb"},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes","author":"Chambergo-Michilot","year":"2022","journal-title":"Vhrm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2020.1808981","article-title":"Cost Utility Analysis of Tisagenlecleucel vs Salvage Chemotherapy in the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma from Singapore's Healthcare System Perspective","volume":"23","author":"Cher","year":"2020","journal-title":"J. Med. Econ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of Antisense Oligonucleotide and Sirna-Based Therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"B22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-Viral Delivery of Zinc Finger Nuclease Mrna Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous Familial Hypercholesterolaemia: New Insights and Guidance for Clinicians to Improve Detection and Clinical Management. A Position Paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy","volume":"34","author":"D\u2019Erasmo","year":"2017","journal-title":"Adv. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"103831","DOI":"10.1016\/j.ejmg.2019.103831","article-title":"Familial Hypercholesterolemia: A Complex Genetic Disease with Variable Phenotypes","volume":"63","author":"Di Taranto","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent Alteration of Pcsk9 with In Vivo Crispr-Cas9 Genome Editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The Promise and Challenge of Therapeutic Genome Editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nmeth.2681","article-title":"Orthogonal Cas9 Proteins for Rna-Guided Gene Regulation and Editing","volume":"10","author":"Esvelt","year":"2013","journal-title":"Nat. Methods"},{"key":"B30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-Frequency Off-Target Mutagenesis Induced by Crispr-Cas Nucleases in Human Cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-Effectiveness of Tisagenlecleucel vs Standard Care in High-Risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada","volume":"6","author":"Furzer","year":"2020","journal-title":"JAMA Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and Metabolic Effects of Angptl3 Antisense Oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/humc.2017.014","article-title":"Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-type and LDLR+\/\u2212 Rhesus Macaques","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/humc.2017.007","article-title":"Nonclinical Pharmacology\/Toxicology Study of Aav8.Tbg.Mldlr and Aav8.Tbg.Hldlr in a Mouse Model of Homozygous Familial Hypercholesterolemia","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A Pilot Study of Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 Aha\/Acc\/Aacvpr\/Aapa\/Abc\/Acpm\/Ada\/Ags\/Apha\/Aspc\/Nla\/Pcna Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113834","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic Acid Delivery for Therapeutic Applications","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41422-020-0303-z","article-title":"Hypercholesterolemia Risk-Associated Gpr146 Is an Orphan G-Protein Coupled Receptor that Regulates Blood Cholesterol Levels in Humans and Mice","volume":"30","author":"Han","year":"2020","journal-title":"Cell. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","article-title":"Alirocumab Efficacy in Patients with Double Heterozygous, Compound Heterozygous, or Homozygous Familial Hypercholesterolemia","volume":"12","author":"Hartgers","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11886-015-0665-x","article-title":"New Approaches in Detection and Treatment of Familial Hypercholesterolemia","volume":"17","author":"Hartgers","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/nat.2017.0666","article-title":"Assessment of the Effects of 2\u2032-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates","volume":"27","author":"Henry","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"B42","volume-title":"The National Academies Collection: Reports Funded by National Institutes of Health","year":"2020"},{"key":"B43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40273-021-01051-4","article-title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review","volume":"39","author":"Ho","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/gt.2016.37","article-title":"Construction of Minicircle DNA Vectors Capable of Correcting Familial Hypercholesterolemia Phenotype in a Ldlr-Deficient Mouse Model","volume":"23","author":"Hou","year":"2016","journal-title":"Gene Ther."},{"key":"B45","volume-title":"Human Genome Editing: Science, Ethics, and Governance","year":"2017"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1038\/s41598-019-43459-1","article-title":"Bile-Duct Proliferation as an Unexpected Side-Effect after Aav2-Ldlr Gene Transfer to Rabbit Liver","volume":"9","author":"Hyt\u00f6nen","year":"2019","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13059-018-1515-0","article-title":"All-in-One Adeno-Associated Virus Delivery and Genome Editing by Neisseria Meningitidis Cas9 In Vivo","volume":"19","author":"Ibraheim","year":"2018","journal-title":"Genome Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/cvr\/cvw010","article-title":"Stable Liver-specific Expression of Human Idol in Humanized Mice Raises Plasma Cholesterol","volume":"110","author":"Ibrahim","year":"2016","journal-title":"Cardiovasc Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1016\/j.ajpc.2021.100157","article-title":"Familial Hypercholesterolemia in Southeast and East Asia","volume":"6","author":"Jackson","year":"2021","journal-title":"Am. J. Prev. Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.08.009","article-title":"Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases","volume":"235","author":"Jayasundera","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A Non-viral Crispr\/Cas9 Delivery System for Therapeutically Targeting Hbv DNA and Pcsk9 In Vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"Crispr-Cas9 DNA Base-Editing and Prime-Editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Ijms"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1038\/mtna.2016.86","article-title":"Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia","volume":"5","author":"Kerr","year":"2016","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2014.12.002","article-title":"Genetic Therapies to Lower Cholesterol","volume":"64","author":"Khoo","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nbt.3852","article-title":"Genome-Wide Target Specificities of Crispr Rna-Guided Programmable Deaminases","volume":"35","author":"Kim","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In Vivo genome Editing with a Small Cas9 Orthologue Derived from Campylobacter Jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1021\/acschembio.7b00710","article-title":"Editing the Genome without Double-Stranded DNA Breaks","volume":"13","author":"Komor","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and Challenges for Antisense Oligonucleotide Therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"Jrnl Inher Metab Disea"},{"key":"B59","doi-asserted-by":"publisher","first-page":"F1000Res2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In Vivo genome Editing in Animals Using AAV-CRISPR System: Applications to Translational Research of Human Disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jgm.554","article-title":"Gene Therapy with Novel Adeno-Associated Virus Vectors Substantially Diminishes Atherosclerosis in a Murine Model of Familial Hypercholesterolemia","volume":"6","author":"Lebherz","year":"2004","journal-title":"J. Gene Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/gt.2013.38","article-title":"Pegylated Helper-dependent Adenoviral Vector Expressing Human Apo A-I for Gene Therapy in Ldlr-Deficient Mice","volume":"20","author":"Leggiero","year":"2013","journal-title":"Gene Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41434-019-0061-z","article-title":"Helper-Dependent Adenovirus-Mediated Gene Transfer of a Secreted Ldl Receptor\/Transferrin Chimeric Protein Reduces Aortic Atherosclerosis in Ldl Receptor-Deficient Mice","volume":"26","author":"Leggiero","year":"2019","journal-title":"Gene Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/ATVBAHA.116.308456","article-title":"Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography","volume":"37","author":"Li","year":"2017","journal-title":"Atvb"},{"key":"B64","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40256-014-0077-0","article-title":"Mipomersen Is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials","volume":"14","author":"Li","year":"2014","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1038\/s41598-018-27248-w","article-title":"Familial Hypercholesterolemia in Very Young Myocardial Infarction","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jacl.2016.08.013","article-title":"Identification of Familial Hypercholesterolemia in Patients with Myocardial Infarction: A Chinese Cohort Study","volume":"10","author":"Li","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.7150\/thno.49874","article-title":"Exosome-Based Ldlr Gene Therapy for Familial Hypercholesterolemia in a Mouse Model","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41467-018-07988-z","article-title":"Genome-Wide Profiling of Adenine Base Editor Specificity by Endov-Seq","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/jco.2018.79.0642","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"Jco"},{"key":"B70","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","article-title":"The Crispr-Cas Toolbox and Gene Editing Technologies","volume":"82","author":"Liu","year":"2022","journal-title":"Mol. Cell."},{"key":"B71","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-020-2928-y","article-title":"Feeding Induces Cholesterol Biosynthesis via the Mtorc1-Usp20-Hmgcr Axis","volume":"588","author":"Lu","year":"2020","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/gt.2013.58","article-title":"Therapeutic Expression of Hairpins Targeting Apolipoprotein B100 Induces Phenotypic and Transcriptome Changes in Murine Liver","volume":"21","author":"Maczuga","year":"2014","journal-title":"Gene Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"100300","DOI":"10.1016\/j.jhepr.2021.100300","article-title":"Novel Vectors and Approaches for Gene Therapy in Liver Diseases","volume":"3","author":"Maestro","year":"2021","journal-title":"JHEP Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/MOL.0000000000000755","article-title":"Inhibition of Angiopoietin-like 3 for the Management of Severe Hypercholesterolemia","author":"Mohamed","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In Vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/sj.gt.3302310","article-title":"Low-Density Lipoprotein Receptor Gene Therapy Using Helper-dependent Adenovirus Produces Long-Term Protection against Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia","volume":"11","author":"Nomura","year":"2004","journal-title":"Gene Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1053\/jhep.2003.50183","article-title":"Repopulation of Rat Liver by Fetal Hepatoblasts and Adult Hepatocytes Transduced Ex Vivo with Lentiviral Vectors","volume":"37","author":"Oertel","year":"2003","journal-title":"Hepatology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1038\/s41598-019-41056-w","article-title":"Function and Immunogenicity of Gene-Corrected Ipsc-Derived Hepatocyte-like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia","volume":"9","author":"Okada","year":"2019","journal-title":"Sci. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12041-016-0636-z","article-title":"Improving Lipoprotein Profiles by Liver-Directed Gene Transfer of Low Density Lipoprotein Receptor Gene in Hypercholesterolaemia Mice","volume":"95","author":"Ou","year":"2016","journal-title":"J. Genet."},{"key":"B83","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","article-title":"Genetic Determinants of Inherited Susceptibility to Hypercholesterolemia - a Comprehensive Literature Review","volume":"16","author":"Paththinige","year":"2017","journal-title":"Lipids Health Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1089\/hum.2018.014","article-title":"Results at 5 Years after Gene Therapy for Rpe65-Deficient Retinal Dystrophy","volume":"29","author":"Pennesi","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMra1800729","article-title":"A New Class of Medicines through DNA Editing","volume":"380","author":"Porteus","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an Apolipoprotein B Synthesis Inhibitor, for Lowering of Ldl Cholesterol Concentrations in Patients with Homozygous Familial Hypercholesterolaemia: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11886-021-01514-2","article-title":"Beyond Statins and Pcsk9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias","volume":"23","author":"Rached","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"B90","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In Vivo genome Editing Using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated Ldl Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base Editing: Precision Chemistry on the Genome and Transcriptome of Living Cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In Vivo adenine Base Editing of PCSK9 in Macaques Reduces LDL Cholesterol Levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"104653","DOI":"10.1016\/j.phrs.2020.104653","article-title":"Pharmacological Aspects of Angptl3 and Angptl4 Inhibitors: New Therapeutic Approaches for the Treatment of Atherogenic Dyslipidemia","volume":"153","author":"Ruscica","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and Safety of Voretigene Neparvovec (AAV2-hRPE65v2) in Patients with RPE65 -mediated Inherited Retinal Dystrophy: a Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 Inhibitors: Clinical Evidence and Implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"Crispr-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fcvm.2020.00113","article-title":"The Prevalence of Familial Hypercholesterolemia (Fh) in Chinese Patients with Acute Myocardial Infarction (Ami): Data from Chinese Acute Myocardial Infarction (Cami) Registry","volume":"7","author":"Shi","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140989","article-title":"Hepatocyte-Specific Suppression of Angptl4 Improves Obesity-Associated Diabetes and Mitigates Atherosclerosis in Mice","volume":"131","author":"Singh","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcp.2017.02.006","article-title":"Rev-Erb Regulation of Cholesterologenesis","volume":"131","author":"Sitaula","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous Autosomal Dominant Hypercholesterolaemia in the Netherlands: Prevalence, Genotype-Phenotype Relationship, and Clinical Outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"key":"B102","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in Patients with Familial Hypercholesterolaemia (The Akka Trial): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes & Endocrinol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s41669-018-0102-3","article-title":"Strimvelis for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation","volume":"3","author":"South","year":"2019","journal-title":"PharmacoEconomics Open"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-Iii Reduction in Subjects with Moderate Hypertriglyceridaemia and at High Cardiovascular Risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.ymthe.2021.02.020","article-title":"Long-Term Stable Reduction of Low-Density Lipoprotein in Nonhuman Primates Following In Vivo Genome Editing of Pcsk9","volume":"29","author":"Wang","year":"2021","journal-title":"Mol. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nbt.4182","article-title":"Meganuclease Targeting of Pcsk9 in Macaque Liver Leads to Stable Reduction in Serum Cholesterol","volume":"36","author":"Wang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"Crispr-Cas9 Targeting of Pcsk9 in Human Hepatocytes In Vivo-Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Atvb"},{"key":"B108","doi-asserted-by":"publisher","first-page":"A15751","DOI":"10.1161\/circ.142.suppl_3.15751","article-title":"Pharmacodynamic Effect of Aro-Ang3, an Investigational Rna Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients with Hypercholesterolemia","volume":"142","author":"Watts","year":"2020","journal-title":"Circulation"},{"key":"B109","first-page":"E987","article-title":"Rna Interference Targeting Hepatic Angiopoietin-like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and Ldl-C in Human Subjects","volume":"140","author":"Watts","year":"2019","journal-title":"Circ. Baltim."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1097\/MJT.0000000000000898","article-title":"Poor Response to Alirocumab in a Patient with Homozygous Familial Hypercholesterolemia","volume":"26","author":"Wu","year":"2019","journal-title":"Am. J. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"901","DOI":"10.7754\/clin.lab.2012.121104","article-title":"Acute Myocardial Infarction in an 8-Year Old Male Child with Homozygous Familiar Hypercholesterolemia: Laboratory Findings and Response to Lipid-Lowering Drugs","volume":"59","author":"Wu","year":"2013","journal-title":"Clin. Lab."},{"key":"B112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/v11010028","article-title":"Viral Delivery Systems for Crispr","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"B113","doi-asserted-by":"publisher","first-page":"840358","DOI":"10.3389\/fcvm.2022.840358","article-title":"Targeting Apoc3 Paradoxically Aggravates Atherosclerosis in Hamsters with Severe Refractory Hypercholesterolemia","volume":"9","author":"Xu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.7150\/thno.41580","article-title":"Progress, Opportunity, and Perspective on Exosome Isolation - Efforts for Efficient Exosome-Based Theranostics","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-Guided Chemical Modification of Guide Rna Enables Potent Non-viral In Vivo Genome Editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"106878","DOI":"10.1016\/j.vph.2021.106878","article-title":"Inducible Degrader of Ldlr: A Potential Novel Therapeutic Target and Emerging Treatment for Hyperlipidemia","volume":"140","author":"Yu","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In Vivo AAV-CRISPR\/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood-2010-06-291716","article-title":"Angiopoietin-Like Protein 3 Supports the Activity of Hematopoietic Stem Cells in the Bone Marrow Niche","volume":"117","author":"Zheng","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.911429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T03:13:59Z","timestamp":1654744439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.911429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":118,"alternative-id":["10.3389\/fgene.2022.911429"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.911429","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"911429"}}